Cargando...
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...
Gardado en:
| Publicado en: | Circulation |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/ https://ncbi.nlm.nih.gov/pubmed/32078382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|